Gilead’s recently departed CEO John Milligan capped a year marked by setbacks, a major write-off and big questions about the company's future under a new helmsman with what currently stands as the biggest pay package of all the major league CEOs in biopharma.
Image: John Milligan speaks to Bloomberg in 2014 Bloomberg
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 45,000+ biopharma pros who read Endpoints News by email every day.Free Subscription